<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02308527</url>
  </required_header>
  <id_info>
    <org_study_id>RG_11-087</org_study_id>
    <secondary_id>2012-000072-42</secondary_id>
    <nct_id>NCT02308527</nct_id>
  </id_info>
  <brief_title>Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children</brief_title>
  <acronym>BEACON</acronym>
  <official_title>A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imagine for Margo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether Bevacizumab (an anti-VEGF monoclonal
      antibody) added to a backbone chemotherapy regimen (Temozolomide, Irinotecan-Temozolomide or
      Topotecan-Temozolomide) demonstrates activity in children with relapsed or refractory
      neuroblastoma. Also, to investigate whether the addition of Irinotecan or Topotecan to
      Temozolomide increases the activity of chemotherapy.The primary objective of the study is the
      best response (Complete Response or Partial Response) while trial treatment, within 18 or 24
      weeks depending on the arm of the trial the participant is randomised to. Secondary endpoints
      are assessing the side effects, the length of time before progression (Progression Free
      Survival) and overall survival (OS).

      This trial will address two important questions:

        -  does targeting blood vessel development using bevacizumab, (a monoclonal antibody
           against the Vascular Endothelial Growth Factor (VEGF)), add to the effect on a tumour
           when used with existing chemotherapy, compared to the effect of the existing
           chemotherapy alone (temozolomide)?

        -  does the addition of a second chemotherapy drug (irinotecan or topotecan) increase the
           effect on a tumour compared to the effect of one alone (temozolomide) Patients aged 1-21
           years of age with relapsed or refractory high-risk neuroblastoma are randomised to one
           of six treatment arms: Temozolomide (T), irinotecan-temozolomide (IT), bevacizumab-T
           (BT), BIT (bevacizumab-IT), temozolomide-topotecan (TTo) or
           bevacizumab-temozolomide-topotecan (BTTo).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international open-label, randomised, multicentre phase II trial of temozolomide ±
      irinotecan, with or without bevacizumab, for the treatment of patients with relapsed or
      refractory neuroblastoma. The study will evaluate the safety and activity of these
      combinations.

      Patients will be registered into the trial and randomised at the same time to one of the
      following six arms (approximately 30 patients per arm):

      T: Temozolomide BT: Bevacizumab + Temozolomide IT: Irinotecan + Temozolomide BIT: Bevacizumab
      + Irinotecan + Temozolomide TTo: Temozolomide + Topotecan BTTo: Bevacizumab + Temozolomide +
      Topotecan

      Randomisation will be via a secure on-line computer-based system at the Cancer Research
      Clinical Trial Unit (CRCTU), University of Birmingham, United Kingdom (UK) and patients will
      be allocated in a 1:1 ratio. Minimisation will be used to ensure balance across the arms for
      the important prognostic factors as described by London et al. [10]: a) relapsed, refractory
      disease, b) early (&lt; 18 months), late relapse (≥18 months) and c) measurable versus evaluable
      disease (i.e. disease evaluated according to RECIST versus disease detectable only by MIBG
      scanning with or without bone marrow involvement as detected by local morphology) Patients
      will receive treatment for 6 courses, lasting 18 or 24 weeks depending on the arm of the
      trial that they are randomised to.

      Patients with a response (CR, PR) or stable disease (SD) while on the BEACON-Neuroblastoma
      trial will receive 6 cycles of trial treatment. If the patient has achieved a satisfactory
      response (i.e. CR, PR or SD) with acceptable toxicity, treatment may be extended beyond 6
      cycles (up to 12 cycles) after discussion with the Sponsor and the Chief Investigator (CI).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best response (Complete Response or Partial Response) while on trial treatment, within 18 or 24 weeks depending on the arm of the trial participant is randomised to.</measure>
    <time_frame>Within 18 or 24 weeks depending on the arm of the trial the participant is randomised to.</time_frame>
    <description>To test whether bevacizumab added to a backbone chemotherapy regimen (temozolomide, irinotecan-temozolomide or topotecan-temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma To test whether the addition of irinotecan to temozolomide increases the activity of chemotherapy in children with relapsed or refractory neuroblastoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the toxicity of the regimens</measure>
    <time_frame>Assessment will be after 30 days after treatment or end of trial</time_frame>
    <description>Safety of the regimens: Incidence and severity of Adverse Events (AE)s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of the regimens</measure>
    <time_frame>Assessment will be after 30 days after treatment or end of trial</time_frame>
    <description>Safety of the regimens: Progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the overall safety of the regimens</measure>
    <time_frame>Assessment will be after 30 days after treatment or end of trial</time_frame>
    <description>Safety of the regimens: Overall survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Temozolomide Days 1-5 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irinotecan + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab + Irinotecan + Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temozolomide + Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Temozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab + Temozolomide + Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Bevacizumab + Temozolomide</arm_group_label>
    <arm_group_label>Bevacizumab + Temozolomide + Topotecan</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_label>Bevacizumab + Temozolomide</arm_group_label>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Irinotecan + Temozolomide</arm_group_label>
    <arm_group_label>Bevacizumab + Irinotecan + Temozolomide</arm_group_label>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Irinotecan + Temozolomide</arm_group_label>
    <arm_group_label>Bevacizumab + Irinotecan + Temozolomide</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Bevacizumab + Irinotecan + Temozolomide</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Temozolomide + Topotecan</arm_group_label>
    <arm_group_label>Bevacizumab + Temozolomide + Topotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression</description>
    <arm_group_label>Temozolomide + Topotecan</arm_group_label>
    <arm_group_label>Bevacizumab + Temozolomide + Topotecan</arm_group_label>
    <other_name>Temodal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Histologically proven neuroblastoma as per International Neuroblastoma Staging System
             (INSS) definition

          -  Relapsed: any relapsed or progressed high-risk neuroblastoma

          -  Refractory high risk disease: Lack of adequate response to frontline therapy that
             precludes the patient from proceeding to consolidation therapies

          -  Measurable disease by cross sectional imaging (RECIST) or evaluable disease

          -  Age ≥1 to ≤21 years

          -  Informed consent from patient, parent or guardian

          -  Performance Status:Lansky ≥ 50%, Karnofsky ≥ 50% or Eastern Cooperative Oncology Group
             ≤3 (Patients who are unable to walk because of paralysis, but who are able to sit
             upright unassisted in a wheelchair, will be considered ambulatory for the purpose of
             assessing performance score)

          -  Life expectancy of ≥12 weeks

          -  No bone marrow disease: Platelets ≥75 x 10^9/L (unsupported for 72 hours), absolute
             neutrophil count ≥0.75 x10^9/L (no G-cerebrospinal fluid support for 72 hours),
             Haemoglobin ≥7.5 g/dL (transfusions allowed) Bone marrow disease: Platelets ≥50
             x10^9/L (unsupported for 72 hours), absolute neutrophil count (ANC) ≥0.5 x 10^9/L (no
             granulocyte colony stimulating factor (G-CSF) for 72 hours), Haemoglobin ≥7.5 g/dL
             (transfusions allowed)

          -  Renal function (within 72 hours of eligibility assessment): Absence of clinically
             significant proteinuria (early morning urine dipstick &lt;2+). When the dipstick
             urinalysis shows a proteinuria ≥2+, a protein:creatinine (Pr/Cr) ratio must be &lt;0.5 or
             a 24 hour protein excretion must be &lt;0.5g

          -  Serum creatinine ≤ 1.5 upper limit of normal for age, if higher, a calculated
             glomerular filtration rate (radioisotope) must be ≥60 ml/min/1.73 m2

          -  Liver function (within 72 hours of eligibility assessment): aspartate aminotransferase
             (AST) or Alanine Aminotransferase (ALT) ≤2.5 ULN and Total bilirubin ≤1.5 upper limit
             of normal (ULN). In case of liver metastases, AST or ALT ≤5 ULN and Total bilirubin
             ≤2.5 ULN

          -  Cardiac function, shortening fraction ≥29% on echocardiogram

          -  Coagulation, patients not on anticoagulation must have an international normalized
             ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 ULN for age.
             Anti-coagulation is permitted as long as the INR or APTT is within therapeutic limits
             (according to the medical standard of the institution) and the patient has been on a
             stable dose of anticoagulants for at least two weeks at the time of study enrolment

          -  Blood pressure below 95th centile for age and sex. Use of antihypertensive medication
             is permitted

          -  Males or females of reproductive potential may not participate unless they agree to
             use an effective contraceptive method, for the duration of study therapy and for up to
             6 months after the last dose of trial drugs. A negative urine pregnancy test must be
             obtained within 72 hours prior to dosing in females who are post-menarche

        Exclusion Criteria:

          -  Previous treatment with bevacizumab, temozolomide, irinotecan or any combination of
             these drugs

          -  Known hypersensitivity to: Any study drug or component of the formulation, Chinese
             hamster ovary products or other recombinant human or humanised antibodies

          -  Prior severe arterial thrombo-embolic events (e.g. cardiac ischemia, cerebral vascular
             accident, peripheral arterial thrombosis)

          -  Any ongoing arterial thrombo-embolic events

          -  Patient &lt;48 hours post bone marrow aspirate/trephine, &lt;48 hours post central line
             insertion, &lt;Four weeks post major surgery, &lt;One week post core biopsy, &lt;Two weeks from
             prior chemotherapy, &lt;Six weeks from prior craniospinal or meta-iodobenzylguanidine
             (MIBG) therapy and two weeks from radiotherapy to the tumour bed, &lt;Eight weeks from
             prior myeloablative therapy with haematopoietic stem cell rescue (autologous stem cell
             transplant), &lt;Three months from prior allogeneic stem cell transplant, &lt;Two weeks from
             last administration of an investigational medicinal product (IMP) in an IMP-trial

          -  Bleeding metastases

          -  Invasion of major blood vessels

          -  Use of enzyme inducing anticonvulsants within 72 hours of eligibility assessment

          -  History or evidence of inherited bleeding diathesis or significant coagulopathy at
             risk of bleeding (i.e. in the absence of therapeutic anticoagulation)

          -  History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or
             active gastrointestinal bleeding within 6 months prior to study enrolment

          -  Pregnant or lactating patient

          -  Any uncontrolled medical condition that poses an additional risk to the patient

          -  Low probability of treatment compliance

          -  Planned immunisation with live vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucas Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucas Moreno, MD</last_name>
    <phone>0121 4143788</phone>
    <email>lmorenom@ext.cnio.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keith Wheatley, PhD</last_name>
    <phone>0121 4143845</phone>
    <email>K.Wheatley@bham.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Anna Children's Hospital and CCRI/Studies and Statistics</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Ladenstein, MD</last_name>
      <phone>43 1 40470 4750</phone>
      <email>ruth.ladenstein@ccri.at</email>
    </contact>
    <investigator>
      <last_name>Ruth Ladenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten Nysom, MD</last_name>
      <phone>45 35 45 08 09</phone>
      <email>Karsten.Nysom@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Karsten Nysom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herve Rubie, MD</last_name>
      <phone>33 534 55 86 11</phone>
      <email>rubie.h@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Herve Rubie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Ladys Children's Hospital Dublin</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cormac Owens, MD</last_name>
      <phone>35 31 409 6659</phone>
      <email>cormac.owens@olchc.ie</email>
    </contact>
    <investigator>
      <last_name>Cormac Owens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gseu</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurora Castellano, MD</last_name>
      <email>aurora.castellano@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Aurora Castellano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigacion Sanitaria</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Castel, MD</last_name>
      <phone>34 963 862 758</phone>
      <email>castel_vic@gva.es</email>
    </contact>
    <investigator>
      <last_name>Victoria Castel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swiss Paediatric Oncology Group</name>
      <address>
        <city>Bern</city>
        <zip>3008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Gerber</last_name>
      <phone>+41 (0)31 508 42 38</phone>
      <email>'nicolas.gerber@kispi.uzh.ch'</email>
    </contact>
    <contact_backup>
      <last_name>TuMy DiepLai</last_name>
      <phone>+41 (0)31 508 42 38</phone>
      <email>Tu-My.Diep@spog.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas Gerber`</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust and Institute of Cancer Research</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew DJ Pearson, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Lucas Moreno, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andrew DJ Pearson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>December 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Young adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

